氯法齐明治疗重度免疫抑制宿主微小巴贝虫感染有前景
研究在重度联合免疫缺陷小鼠中测试口服氯法齐明对微小巴贝虫感染的疗效。持续单药治疗可遏制虫血症上升并实现根治,7天给药使虫血症上升延迟22天,14天给药足以清除阿托伐醌耐药虫株所致的高水平虫血症。
要点
- 氯法齐明持续单药可清除免疫缺陷小鼠的微小巴贝虫感染。
- 7天氯法齐明使虫血症上升延迟22天。
- 14天氯法齐明可解决阿托伐醌耐药虫株所致高虫血症。
核心结论
- 氯法齐明对免疫缺陷宿主的微小巴贝虫感染有效。
研究设计与样本
- 采用重度联合免疫缺陷小鼠,感染107个微小巴贝虫感染的红细胞,口服氯法齐明,通过吉姆萨染色血涂片镜检或巢式PCR检测寄生虫。
主要发现
- 不间断氯法齐明单药治疗遏制虫血症上升并实现根治。
- 治疗第10天清除微小巴贝虫寄生虫,第50天清除虫体DNA。
- 7天氯法齐明给药使虫血症上升延迟22天,该上升由细胞色素b基因未突变的分离株引起。
- 14天氯法齐明给药足以解决阿托伐醌耐药微小巴贝虫所致的高水平虫血症。
临床怎么用
- 提示氯法齐明可作为免疫缺陷患者微小巴贝虫感染的潜在治疗选择。
- 对阿托伐醌耐药虫株所致高虫血症,14天氯法齐明方案可能有效。
局限性
- 需进一步临床前研究确定氯法齐明治疗巴贝虫病的最小剂量和给药方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Persistent and relapsing babesiosis caused by Babesia microti often occurs in immunocompromised patients, and has been associated with resistance to antimicrobial agents such as atovaquone. Given the rising incidence of babesiosis in the United States, novel drugs are urgently needed. In the current study, we tested whether clofazimine (CFZ), an antibiotic used to treat leprosy and drug-resistant tuberculosis, is effective against B. microti. METHODS: Mice with severe combined immunodeficiency were infected with 107B. microti-infected erythrocytes. Parasites were detected by means of microscopic examination of Giemsa-stained blood smears or nested polymerase chain reaction. CFZ was administered orally. RESULTS: Uninterrupted monotherapy with CFZ curtailed the rise of parasitemia and achieved radical cure. B. microti parasites and B. microti DNA were cleared by days 10 and 50 of therapy, respectively. A 7-day administration of CFZ delayed the rise of parasitemia by 22 days. This rise was caused by B. microti isolates that did not carry mutations in the cytochrome b gene. Accordingly, a 14-day administration of CFZ was sufficient to resolve high-grade parasitemia caused by atovaquone-resistant B. microti parasites. CONCLUSIONS: Clofazimine is effective against B. microti infection in the immunocompromised host. Additional preclinical studies are required to identify the minimal dose and dosage of CFZ for babesiosis.
引用
- Tuvshintulga B, Vannier E, Tayebwa DS, et al. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. J Infect Dis. 2020. PMID: 32310272. doi:10.1093/infdis/jiaa195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。